Publications by authors named "Federico Gatti"
The study aims at defining the factors affecting the clinicians' decision of changing or confirming the treatment options for frail patients in polytherapy, supporting prescribing patterns, thus also figuring out if the inclination of the clinicians towards digital solutions (INTERCheckWEB) and specific guidelines, could play a role in their decision. A literature review was performed, revealing the main individual, organizational and decisional factors, impacting on the clinicians' propensity to change the current patients' therapy: the clinician perceptions of support in case of clinical guidelines use or INTERCheckWEB use were studied. A qualitative approach was implemented, and thirty-five clinicians completed a questionnaire, aimed at evaluating fifteen different clinical cases, defining if they would change the patient's current therapy depending on the level of information received.
View Article and Find Full Text PDFBackground And Aims: INTERCheckWEB is one of the most outstanding digital technologies, that could be implemented at the hospital level, supporting the clinicians in the evaluation of the therapy appropriateness, reducing the potentially inappropriate prescriptions, for the improvement of the clinical decision-making process. The paper aims at investigating the relationship between clinicians' behaviors towards digital decision support system in therapy appropriateness for elderly patients in polytherapy in medical departments, defining the factors that could influence clinicians to use INTERCheckWEB, for supporting drugs' prescription.
Methods: A questionnaire was administered to 70 clinicians referring to Internal Medicine wards, of four Italian hospitals.
Background: Iron deficiency anaemia is a public health problem. In case oral iron treatment is ineffective, poorly tolerated or contraindicated, the intravenous route becomes the first choice. The aim of the study was to evaluate the shift between ferrous gluconate (FG) and ferric carboxymaltose (FCM) usage at our hospitals over the years.
View Article and Find Full Text PDFArticle Synopsis
- Treatment of genotype-3 HCV is challenging, and a study aimed to compare real-life outcomes of three antiviral regimens: SOF+DAC, SOF/VEL, and GLE/PIB.
- The study analyzed 2082 patients, finding that overall response rates after 12 weeks were similar across treatments, with SOF/VEL showing better outcomes only when ribavirin was not included in the regimen.
- The findings suggest that there is a shift towards newer, ribavirin-free treatments which could potentially simplify the management of this difficult-to-treat HCV genotype without compromising success rates.
Article Synopsis
- The study evaluates the effectiveness and safety of the drug combination sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for treating HCV patients who previously failed direct-acting antivirals (DAAs) in a real-life setting across 27 centers in Northern Italy.
- A total of 179 patients were treated, with a 91% overall success rate achieving sustained viral response (SVR12); common issues included cirrhosis and previous liver cancer as predictors of treatment failure, while side effects were relatively low.
- The findings support that SOF/VEL/VOX is a highly effective and safe option for retreating
Article Synopsis
- The study aimed to assess the effectiveness and safety of the combination therapy glecaprevir/pibrentasvir (G/P) for hepatitis C patients in a real-world setting, as previous research was limited to clinical trials.
- A total of 723 patients, mostly treated for 8 weeks, were analyzed, showing high sustained virological response (SVR) rates of 94% overall and 99.3% in per-protocol analysis, although some discrepancies were noted among subgroups.
- Mild adverse effects were observed in about 8.3% of patients, and the study noted a low withdrawal rate due to side effects, with 3 patients dying from unrelated